全文获取类型
收费全文 | 7453篇 |
免费 | 444篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 268篇 |
妇产科学 | 178篇 |
基础医学 | 1238篇 |
口腔科学 | 107篇 |
临床医学 | 582篇 |
内科学 | 1813篇 |
皮肤病学 | 177篇 |
神经病学 | 784篇 |
特种医学 | 144篇 |
外科学 | 629篇 |
综合类 | 23篇 |
预防医学 | 630篇 |
眼科学 | 156篇 |
药学 | 578篇 |
中国医学 | 37篇 |
肿瘤学 | 534篇 |
出版年
2023年 | 49篇 |
2022年 | 47篇 |
2021年 | 248篇 |
2020年 | 163篇 |
2019年 | 223篇 |
2018年 | 239篇 |
2017年 | 201篇 |
2016年 | 206篇 |
2015年 | 245篇 |
2014年 | 327篇 |
2013年 | 399篇 |
2012年 | 632篇 |
2011年 | 633篇 |
2010年 | 323篇 |
2009年 | 268篇 |
2008年 | 480篇 |
2007年 | 538篇 |
2006年 | 503篇 |
2005年 | 468篇 |
2004年 | 434篇 |
2003年 | 387篇 |
2002年 | 365篇 |
2001年 | 47篇 |
2000年 | 30篇 |
1999年 | 43篇 |
1998年 | 53篇 |
1997年 | 39篇 |
1996年 | 34篇 |
1995年 | 47篇 |
1994年 | 34篇 |
1993年 | 35篇 |
1992年 | 31篇 |
1991年 | 19篇 |
1990年 | 16篇 |
1989年 | 13篇 |
1988年 | 19篇 |
1987年 | 15篇 |
1986年 | 14篇 |
1985年 | 7篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 8篇 |
1981年 | 9篇 |
1980年 | 5篇 |
1978年 | 8篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1967年 | 2篇 |
排序方式: 共有7950条查询结果,搜索用时 17 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
3.
Francisco José Álvarez García María José Cilleruelo Ortega Javier Álvarez Aldeán María Garcés-Sánchez Nuria García Sánchez Elisa Garrote Llanos Ángel Hernández Merino Antonio Iofrío de Arce Abián Montesdeoca Melián María Luisa Navarro Gómez Jesús Ruiz-Contreras 《Anales de pediatría (Barcelona, Spain : 2003)》2021,94(1):53.e1-53.e10
The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence.The 2 + 1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2 + 1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks.Rotavirus vaccine should be systematic for all infants.Meningococcal B vaccine, with a 2 + 1 schedule, should be included in routine calendar.In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups.Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine.Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders. 相似文献
4.
Deepti Bettampadi Luisa L. Villa Eduardo L. Ponce Jorge Salmeron Bradley A. Sirak Martha Abrahamsen Julie A. Rathwell Richard R. Reich Anna R. Giuliano 《International journal of cancer. Journal international du cancer》2020,146(11):3026-3033
Incidence of human papillomavirus (HPV) attributable oropharyngeal cancers (OPCs) has been increasing globally, especially among men in high-income countries. There is a lack of studies comparing oral HPV prevalence by age and country among healthy men. The purpose of our study was to assess oral HPV prevalence by country and age. Participants of the HPV Infection in Men Study (HIM), a cohort of 3,098 healthy men from São Paulo, Brazil, Cuernavaca, Mexico and Tampa, USA, were studied. Oral HPV prevalence and type distribution were assessed using the SPF10 PCR-DEIA-LiPA25 system. The prevalence of any HPV in Brazil, Mexico and the US was 8.7% (95% CI: 7.1%, 10.4%), 10.0% (95% CI: 8.3%, 12.1%) and 7.6% (95% CI: 5.9%, 9.5%), respectively, while the prevalence of high-risk HPV was 5.3% (95% CI: 4.1%, 6.7%), 7.3% (95% CI: 5.7%, 9.0%) and 5.4% (95% CI: 4.0%, 7.0%), respectively. No significant differences in prevalence of grouped HPV types were observed by country despite significant differences in sexual behaviors. However, the age-specific prevalence of oral HPV differed by country. Brazilian (6.0% [95% CI: 3.4%, 9.7%]) and Mexican (9.2% [95% CI: 5.6%, 14.0%]) participants had peak high-risk HPV prevalence among men aged 41–50 years whereas the US participants had peak prevalence at ages 31–40 years (11.0% [95% CI: 6.4%, 17.3%]). In conclusion, oral HPV prevalence was low with no difference in overall prevalence observed by country. Factors associated with the differences in oral HPV age-patterning by country and sexual orientation require further study. 相似文献
5.
Matheus Frana Perazzo Ana Luisa Caldas Otoni Matheus Silva Costa Ana Flvia Granville‐Granville Saul Martins Paiva Paulo Antnio Martins‐Júnior 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2019,29(6):692-711
6.
Clinical Rheumatology - We report a case of a 56-year-old woman with an alleged diagnosis of an acute coronary syndrome that was later correctly identified in our Cardiology Unit as antisynthetase... 相似文献
7.
8.
Stefano Cascinu György Bodoky Kei Muro Eric Van Cutsem Sang Cheul Oh Gunnar Folprecht Sumitra Ananda Gustavo Girotto Zev A. Wainberg Maria Luisa Limon Miron Jaffer Ajani Ran Wei Astra M. Liepa Roberto Carlesi Michael Emig Atsushi Ohtsu 《The oncologist》2021,26(3):e414-e424
BackgroundIn the intent‐to‐treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation.Materials and MethodsTumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality‐of‐Life Questionnaire‐Core 30 (EORTC QLQ‐C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR.ResultsIn both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation.ConclusionTreatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. .Implications for PracticeRamucirumab plus paclitaxel is a recognized standard of care as it improves survival for patients with advanced gastric or gastroesophageal junction adenocarcinoma who have been previously treated with recommended first‐line therapy. These additional data on tumor response demonstrate a positive association between tumor shrinkage and symptom palliation in a patient population that is often symptomatic. These observations included patients with nonmeasurable disease, a group of patients often underrepresented in clinical trials. This knowledge can inform treatment decisions, which align individual patient characteristics and needs with demonstrated benefits. NCT01170663相似文献
9.
10.
ObjectiveThe aim was to adapt an instrument that evaluates the relationship between young individuals and health professionals to the Brazilian population, which will be called the Escala de Avaliação de Vínculo entre Jovens e Profissionais de Saúde (Youth Connectedness to Provider scale).MethodThe questionnaire known as the Youth Connectedness to Provider scale consists of seven Likert-like questions. The translation, back-translation, evaluation by ten specialists, and pre-test with 43 adolescents and young adults aged between 10 and 24 years were performed to assess the clarity and reliability of meanings. The content validity index was calculated for each question. Subsequently, the clinical validation was performed with 83 patients aged 10–24 years old and Cronbach's alpha coefficient was calculated.ResultsA content validity index >0.8 (considered satisfactory) was obtained for all items analyzed by experts and adolescents. At the clinical validation, it showed a high internal consistency (Cronbach’s alpha = 0.76). The questions showed a good correlation, except for the question about judgment (Spearman’s rho = 0.03–0.19).ConclusionsThe scale adaptation showed an adequate agreement rate at the translation evaluation and a good reliability index in the questions. This instrument provides information on strengths and topics that require more attention from professionals to improve the relationship with their patients; it can be a valuable parameter in assessing the medical consultation quality. 相似文献